MAPT and Alzheimer disease: With advances in biomarkers, those reflecting AD core pathology, including Aβ42, phosphorylated tau (p-tau) and total tau (t-tau) in cerebrospinal fluid (CSF), can be detected many years before the onset of clinical symptoms (Bateman et al., 2012; Grontvedt et al., 2018).